Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biomarin Pharmaceutical

58.37
-0.0200-0.03%
Post-market: 58.31-0.0600-0.10%19:47 EDT
Volume:1.32M
Turnover:77.66M
Market Cap:11.19B
PE:21.58
High:59.35
Open:58.48
Low:58.22
Close:58.39
Loading ...

Wolfe Research Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
16 Jul

BioMarin Pharmaceutical Is Maintained at Overweight by JP Morgan

Dow Jones
·
15 Jul

BioMarin Pharmaceutical (BMRN) Gets a Buy from J.P. Morgan

TIPRANKS
·
14 Jul

Biomarin Pharmaceutical Inc : Morgan Stanley Cuts Target Price to $97.00 From $105.00

THOMSON REUTERS
·
03 Jul

BioMarin Pharmaceutical Closes Acquisition of Inozyme Pharma

MT Newswires Live
·
01 Jul

Biomarin Announces Completion of Acquisition of Inozyme

THOMSON REUTERS
·
01 Jul

2 Profitable Stocks for Long-Term Investors and 1 to Be Wary Of

StockStory
·
26 Jun

Jefferies Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
26 Jun

BioMarin Pharmaceutical Reports Sustained Efficacy for Hemophilia A Gene Therapy in Five-Year Data

MT Newswires Live
·
24 Jun

BRIEF-BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN®

Reuters
·
24 Jun

BioMarin Pharmaceutical Inc. to Present Long-Term Efficacy and Safety Data of ROCTAVIAN® at International Society on Thrombosis and Haemostasis Congress

Reuters
·
24 Jun

Biomarin Pharmaceutical Inc - No New Safety Signals Observed in 5-Year Roctavian Study

THOMSON REUTERS
·
24 Jun

Biomarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of Roctavian® (Valoctocogene Roxaparvovec-Rvox) at International Society on Thrombosis and Haemostasis 2025 Congress

THOMSON REUTERS
·
24 Jun

BioMarin Pharmaceutical (BMRN) Receives a Buy from Barclays

TIPRANKS
·
10 Jun

Inozyme Pharma Announces Transaction Bonuses for Key Executives Following Merger Agreement

Reuters
·
02 Jun

S&P 500 Futures Rise In Premarket Trading; Trump Media & Tech, Stellantis Lead

Dow Jones
·
27 May

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1

StockStory
·
27 May

Erin Burkhart, GVP and Chief Accounting Officer, Reports Disposal of BioMarin Pharmaceutical Inc. Common Shares

Reuters
·
21 May

Sector Update: Health Care Stocks Rise Friday Afternoon

MT Newswires Live
·
17 May

Leerink bullish on BioMarin following Inozyme deal, expects additional BD

TIPRANKS
·
17 May